Sirona Reports Fiscal 2012 First Quarter Results

• Record first quarter revenues of $258.1 million, up 9.5% compared to prior year, and up 10.2% constant currency.
• First quarter operating income, excluding amortization of $12.3 million totaled $66.6 million, compared to $69.5 million in the prior year.
• Management now anticipates FY12 constant currency revenue growth at upper-end of the announced guidance range of 6% to 8%. OI plus amortization now expected to be in the range of $227 to $234 million (previously $225 to $234 million).

LONG ISLAND CITY, N.Y.--(BUSINESS WIRE)--Sirona (Nasdaq: SIRO), the dental technology leader, today announced its financial results for the quarter ended December 31, 2011.

First Quarter Fiscal 2012 vs. First Quarter Fiscal 2011 Financial Results

Revenue was $258.1 million, an increase of $22.5 million or up 9.5% (up 10.2% on a constant currency basis), with growth rates for the Company's business segments as follows: Imaging Systems increased 23.8% (up 24.3% constant currency); Instruments increased 7.5% (up 8.4% constant currency); Treatment Centers increased 3.0% (up 3.8% constant currency); and CAD/CAM increased 1.0% (up 1.5% constant currency). Revenue in the United States increased 2.0%, while revenues outside the United States increased 12.7% (up 13.6% constant currency), with particularly robust performance in the Asia Pacific region.

Gross profit was $138.8 million, up $8.4 million. Gross profit margin was 53.8% in the first quarter of Fiscal 2012, compared to 55.3% in the prior year. Gross profit margin as a percent of sales was mainly impacted by product mix.

First quarter 2012 operating income excluding amortization expense was $66.6 million (operating income of $54.3 million plus amortization expense of $12.3 million, compared to $69.5 million (operating income of $56.0 million plus amortization expense of $13.5 million) in the first quarter of 2011.

Net income for the first quarter of 2012 was $38.3 million, or $0.67 per diluted share, versus $42.4 million, or $0.75 per diluted share in the prior year period. Non-GAAP earnings per diluted share for the first quarter of 2012 was $0.91 compared to $0.96 in the prior year quarter.

At December 31, 2011, the Company had cash and cash equivalents of $105.7 million and total debt of $130.0 million, resulting in net debt of $24.3 million. This compares to net debt of $22.5 million at September 30, 2011.

Jost Fischer, Chairman and CEO of Sirona commented: “I am pleased to report solid results for the first quarter of fiscal 2012. The Imaging segment led our growth, up 24% constant currency, with continued strong sales of 2D and 3D imaging systems. Revenue growth was particularly strong in the Asia Pacific region, driven by our innovative product line and our expanded presence in these markets. These results demonstrate the effectiveness of our strategy to build out our global sales and service infrastructure and position us well for continued robust revenue growth in the second quarter and for the full fiscal year 2012.”

Fiscal 2012 Guidance

Management now anticipates fiscal year 2012 constant currency revenue growth at the upper-end of the announced guidance range of 6% to 8%. Operating income plus amortization is now expected to be in the range of $227 to $234 million (previously $225 to $234 million).

Conference Call/Webcast Information

Sirona will hold a conference call to discuss its financial results at 8:30 AM Eastern Time on February 3, 2012. The teleconference can be accessed by calling [phone] (domestic) or [phone] (international) using passcode # 92450747. The webcast will be available via the Internet at http://ir.sirona.com and a presentation relating to the call will be available on our website. A replay of the conference call will be available through February 10, 2012 by calling [phone] (domestic) or [phone] (international) using passcode # 46425957. A web archive will be available for 30 days at www.sirona.com.

About Sirona Dental Systems, Inc.

Sirona, the dental technology leader, has served dealers and dentists worldwide for more than 130 years. Sirona develops, manufactures, and markets a complete line of dental products, including CAD/CAM restoration systems (CEREC), digital intra-oral, panoramic and 3D imaging systems, dental treatment centers and handpieces. Visit http://www.sirona.com for more information about Sirona and its products.

This press release contains forward-looking information about Sirona Dental Systems, Inc.’s financial results, guidance and estimates, business prospects, and products and services that involve substantial risks and uncertainties or other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. You can identify these statements by the use of words such as "may," "could," "estimate," "will," "believe," "anticipate," "think," "intend," "expect," "project," "plan," "target," "forecast", and similar words and expressions which identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are not guarantees of future performance and involve known and unknown risks and uncertainties, and other factors. Readers are cautioned not to place undue reliance on such statements, which speak only as of the date hereof. For a discussion of such risks, uncertainties and other matters that could cause actual results to differ materially, including risks relating to, among other factors, the market for dental product and services, pricing, future sales volume of the Company's products, the possibility of changing economic, market and competitive conditions, dependence on products, dependence on key personnel, technological developments, intense competition, market uncertainties, dependence on distributors, ability to manage growth, dependence on key suppliers, dependence on key members of management, government regulation, acquisitions and affiliations and currency exchange rate fluctuations, readers are urged to carefully review and consider various disclosures made by the Company in its Annual Report on Form 10-K and in its reports on Forms 10-Q and 8-K filed with the U.S. Securities and Exchange Commission, which can be accessed through the SEC’s website, www.sec.gov. This presentation contains non GAAP financial measures, which should not be viewed in isolation and do not purport to be an alternative to net income (loss) as an indicator of operating performance or an alternative to cash flows from operating activities as a measure of liquidity. The Company assumes no obligation to and expressly disclaims any obligation to update or revise any forward-looking statements contained in this document to reflect new information or future events or developments after the date any such statement is made.

SIRONA DENTAL SYSTEMS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENT OF INCOME (UNAUDITED)
		Three months ended
		December 31,
		2011			2010
		$'000s (except per share amounts)
Revenue	$	258,116		$	235,646
Cost of sales		119,333			105,232
Gross profit		138,783			130,414
Selling, general and administrative expense		73,646			63,323
Research and development		13,286			13,510
Provision for doubtful accounts and notes receivable		39			68
Net other operating income		(2,500	)		(2,500	)
Operating income		54,312			56,013
Loss/(gain) on foreign currency transactions, net		2,230			(761	)
Loss on derivative instruments		436			1,635
Interest expense, net		903			950
Other expense/(income)		262			(866	)
Income before taxes		50,481			55,055
Income tax provision		11,611			12,112
Net income		38,870			42,943
Less: Net income attributable to noncontrolling interests		593			551
Net income attributable to Sirona Dental Systems, Inc.	$	38,277		$	42,392
Income per share (attributable to Sirona Dental Systems, Inc. common shareholders):
- Basic	$	0.69		$	0.77
- Diluted	$	0.67		$	0.75
Weighted average shares - basic		55,783,648			55,337,040
Weighted average shares - diluted		57,121,505			56,852,620

SIRONA DENTAL SYSTEMS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS
		December 31,			September 30,
		2011			2011
		(unaudited)
		$'000s (except per share amounts)
ASSETS
Current assets
Cash and cash equivalents	$	105,679		$	345,859
Accounts receivable, net of allowance for doubtful accounts
of $1,879 and $1,868, respectively		121,783			97,853
Inventories, net		88,630			93,028
Deferred tax assets		25,466			25,014
Prepaid expenses and other current assets		10,337			15,477
Income tax receivable		2,421			4,193
Total current assets		354,316			581,424
Property, plant and equipment, net of accumulated depreciation
and amortization of $114,749 and $111,832, respectively		126,956			131,044
Goodwill		631,722			653,799
Investments		2,450			2,453
Restricted cash		-			655
Intangible assets, net of accumulated amortization of
$411,084 and $412,428, respectively		324,625			346,442
Other non-current assets		4,877			2,884
Deferred tax assets		7,014			7,427
Total assets	$	1,451,960		$	1,726,128
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities
Trade accounts payable	$	37,048		$	48,697
Short-term debt and current portion of long-term debt		55,011			368,403
Income taxes payable		10,928			6,811
Deferred tax liabilities		693			1,108
Accrued liabilities and deferred income		92,681			110,207
Total current liabilities		196,361			535,226
Long-term debt		75,000			-
Deferred tax liabilities		130,292			138,327
Other non-current liabilities		17,613			16,978
Pension related provisions		47,641			49,677
Deferred income		47,500			50,000
Total liabilities		514,407			790,208
Shareholders' equity
Preferred stock ($0.01 par value; 5,000,000 shares authorized; none issued and outstanding)		0			0
Common stock ($0.01 par value; 95,000,000 shares authorized;
56,353,051 shares issued and 55,707,723 shares outstanding at Dec. 31, 2011; 56,292,420 shares issued and 55,815,323 shares outstanding at Sept. 30, 2011		564			563
Additional paid-in capital		687,517			685,617
Treasury stock (at cost)
645,328 shares held at cost at Dec. 31, 2011; 477,097 shares held at cost at Sept. 30, 2011		(26,770	)		(19,749	)
Excess of purchase price over predecessor basis		(49,103	)		(49,103	)
Retained earnings		341,916			303,639
Accumulated other comprehensive (loss)/income		(19,121	)		11,309
Total Sirona Dental Systems, Inc. shareholders' equity		935,003			932,276
Noncontrolling interests		2,550			3,644
Total shareholders' equity		937,553			935,920
Total liabilities and shareholders' equity	$	1,451,960		$	1,726,128

SIRONA DENTAL SYSTEMS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
		Three months ended
		December 31,
		2011			2010
		$'000s
Cash flows from operating activities
Net income	$	38,870		$	42,943
Adjustments to reconcile net income to net cash provided by operating activities
Depreciation and amortization		19,255			19,207
Loss on derivative instruments		436			1,635
Loss/(gain) on foreign currency transactions		2,230			(761	)
Deferred income taxes		(4,428	)		(5,550	)
Amortization of debt issuance cost		199			303
Share-based compensation expense		2,093			1,911
Changes in assets and liabilities
Accounts receivable		(28,626	)		(26,679	)
Inventories		2,129			(531	)
Prepaid expenses and other current assets		5,022			7,448
Restricted cash		646			14
Other non-current assets		(273	)		(653	)
Trade accounts payable		(10,478	)		(1,734	)
Accrued liabilities and deferred income		(17,060	)		(17,696	)
Other non-current liabilities		193			98
Income taxes receivable		1,741			1,845
Income taxes payable		4,389			1,519
Net cash provided by operating activities		16,338			23,319
Cash flows from investing activities
Investment in property, plant and equipment		(7,875	)		(8,961	)
Proceeds from sale of property, plant and equipment		-			341
Purchase of intangible assets		(66	)		-
Net cash used in investing activities		(7,941	)		(8,620	)
Cash flows from financing activities
Repayments of short-term and long-term debt		(366,646	)		-
Proceeds from borrowings		129,209			-
Purchase of treasury stock		(7,020	)		-
Debt issuance cost		(2,289	)		-
Dividend distributions to noncontrolling interest		(1,689	)		-
Common shares issued under share based compensation plans		464			1,515
Tax effect of common shares exercised under share based compensation plans		(639	)		725
Net cash (used in)/provided by financing activities		(248,610	)		2,240
Change in cash and cash equivalents		(240,213	)		16,939
Effect of exchange rate change on cash and cash equivalents		33			(3,359	)
Cash and cash equivalents at beginning of period		345,859			251,767
Cash and cash equivalents at end of period	$	105,679		$	265,347

Non-GAAP Financial Measures (unaudited)
	Three months ended December 31, 2011
	Pre Tax		Tax Impact*		After Tax			Per Diluted Share
	$'000s
GAAP net income attributable to Sirona Dental Systems, Inc. shareholders					$	38,277	$	0.67
Adjustments
Amortization and depreciation expense resulting from the step-up to fair values of intangible assets related to past business combinations	$	11,959	$	2,751	$	9,208
Unrealized, non-cash loss/(gain) on revaluation of the carrying value of the $-denominated exclusivity fee		2,503		576		1,927
Unrealized, non-cash loss/(gain) on revaluation of the carrying value of short-term intra-group loans		3,347		770		2,577
Non-GAAP adjusted net income attributable to Sirona Dental Systems, Inc. shareholders					$	51,990	$	0.91
	Three months ended December 31, 2010
	Pre Tax		Tax Impact*		After Tax			Per Diluted Share
	$'000s
GAAP net income attributable to Sirona Dental Systems, Inc. shareholders					$	42,392	$	0.75
Adjustments
Amortization and depreciation expense resulting from the step-up to fair values of intangible assets related to past business combinations	$	13,146	$	2,892	$	10,254
Unrealized, non-cash loss/(gain) on revaluation of the carrying value of the $-denominated exclusivity fee		1,408		310		1,098
Unrealized, non-cash loss/(gain) on revaluation of the carrying value of short-term intra-group loans		1,346		296		1,050
Non-GAAP adjusted net income attributable to Sirona Dental Systems, Inc. shareholders					$	54,794	$	0.96

* tax impact calculated using estimated effective tax rate of 23% for first three months of FY12 and 22% for first three months of FY11

To supplement our consolidated financial statements and our business outlook, we use the following non-GAAP financial measures: non-GAAP adjusted net income, and non-GAAP adjusted earnings per diluted share, which exclude, as applicable, amortization and depreciation expense resulting from the step-up to fair values of intangible and tangible assets related to past business combinations, unrealized, non-cash loss/(gain) on revaluation of the carrying value of the $-denominated exclusivity fee, unrealized, non-cash loss/(gain) on revaluation of the carrying value of short-term intra-group loans and any related tax effects.

Management recognizes that the use of these non-GAAP measures has limitations, including the fact that they might not be comparable with similar non-GAAP measures used by other companies and that management must exercise judgment in determining which types of charges and other items should be excluded from its non-GAAP financial measures. Management currently compensates for these limitations by providing full disclosure of each non-GAAP financial measure and a reconciliation to the most directly comparable GAAP measure. The presentation of this financial information is not intended to be considered in isolation or as a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP.

We use these non-GAAP financial measures for financial and operational decision making and as a means to evaluate period-to-period comparisons. Our management believes that these non-GAAP financial measures provide meaningful supplemental information regarding our "core operating performance". Management believes that "core operating performance" represents Sirona’s operating performance in the ordinary, ongoing and customary course of its operations. Accordingly, management excludes from "core operating performance" the impact of acquisition-related intangible depreciation and amortization in order to compare our underlying financial performance to prior periods, certain non-cash charges related to currency revaluation that do not reflect our period-to-period operating performance, and to the extent relevant in a particular period, any other cash or non-cash items that management does not view as indicative of its on-going operating performance. We believe that both management and investors benefit from referring to these non-GAAP financial measures in assessing our performance and when planning, forecasting and analyzing future periods. These non-GAAP financial measures also facilitate management's internal evaluation of period-to-period comparisons. We believe these non-GAAP financial measures are useful to investors both because (1) they allow for greater transparency with respect to key metrics used by management in its financial and operational decision making and (2) they are provided to and used by our institutional investors and the analyst community to facilitate comparisons with prior and subsequent reporting periods.

Constant Currency: We have included certain revenue information in this press release on a constant currency basis. This information is a non-GAAP financial measure. We supplementally present revenue on a constant currency basis because we believe it facilitates a comparison of our operating results from period to period without regard to changes resulting solely from fluctuations in currency rates.

Sirona calculates constant currency revenue growth by comparing current period revenues to prior period revenues with both periods converted at the U.S. Dollar/Euro average foreign exchange rate for each month of the current period. The average exchange rate for the three months ended December 31, 2011, was $1.34934 and varied from $1.37045 to $1.31882. For the three months ended December 31, 2010, an average quarterly exchange rate converting Euro denominated revenues into U.S. Dollars of $1.36034 was applied.